02072nas a2200337   4500000000100000008004100001260001300042653001500055653001000070653001000080653002900090653002200119653001100141653001100152653001200163653001000175653002500185653000900210653001600219653001900235100001200254700001400266700001600280700001400296700001400310245007700324300001000401490000600411520130300417022001401720       1982                            d  c1982 Jun10aAdolescent10aAdult10aChild10aClinical Trials as Topic10aDrug Combinations10aFemale10aHumans10aleprosy10aLiver10aLiver Function Tests10aMale10aMiddle Aged10aPlant Extracts1 aNigam P1 aDayal S G1 aMukhija R D1 aGoyal B M1 aJoshi L D00aHepato-protective role of indigenous drug Liv-52 in lepromatous leprosy.  a36-440 v73 a<p>The present study incorporates a study of 42 cases of lepromatous leprosy for hepatic involvement and role of indigenous herbal preparation in protecting the liver in leprosy. Liver was enlarged in 32 cases which was tender in 8 patients. Alteration in liver function irrespective of extent and duration of the illness (3 months to 10 years with mean duration of illness = 2 years 5 months) was mainly seen as uniform elevation of serum proteins (6.2-9.2 gms%, mean = 7.5 gms%) with hypoalbuminaemia (2.0-4.4 gms%, mean = 2.9 gms%). Highest level of serum bilirubin of 1.6 mg% was detected in 6 cases, emphasising the presence of leprous hepatitis. Raised level of serum transaminases (SGOT = 65.2 IU, SGPT = 78.7 IU) were proportionate to the liver and muscle involvement. Presence of characteristic granulomata in the liver around the central vein, periportal area and even distribution at various locations in the liver lobules were the most significant changes in 12 out of 15 liver tissues. Acid fast M. leprae were demonstrated in 12 patients. The present work emphasises the detection of hepatic involvement in the early stage of the disease and hepato-protective role of indigenous drug Liv-52 in lepromatous leprosy which usually lead to dreaded mutilated complications in the body.</p>  a0100-3283